Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health
Healthcare Communications | Pharmaceutical Executive | Medical Executive | Tech PR | Scientific Executive
Latest Jobs
Exclusive vacancies may not be shown here, please contact Kirsty on +44 1494 818057 or for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Kirsty Morris
Senior Account Manager
+44 1494 818057

Thank you so much for your comprehensive efforts. I must admit it is a refreshing surprise to have such an informative response. I can assure you it is really appreciated.
Shan, 2013

Sanofi's diabetes drug Lyxumia receives CHMP backing

20 November 2012 11:10 in Pharmaceutical Company Product News

Sanofi has received a recommendation for European approval of once-daily Lyxumia for the treatment of adults with type 2 diabetes mellitus.

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has endorsed the therapy to achieve glycaemic control in combination with oral glucose-lowering medicinal products and/or basal insulin, in cases when these, together with diet and exercise, have proven ineffective on their own.

Data from the GetGoal phase III programme has demonstrated the efficacy, safety and tolerability profile of the drug among more than 5,000 test subjects.

Sanofi now expects to receive final European approval of lixisenatide within two or three months, while a US regulatory submission is also planned next month.

Pierre Chancel, senior vice-president for global diabetes at Sanofi, said: "The CHMP positive opinion for Lyxumia marks an important milestone in the development of this compound and brings us one step closer to serving even more patients by expanding the Sanofi diabetes product portfolio."

This comes after the firm recently announced the appointment of Dr Gary Nabel as its new chief scientific officer, joining the company from the US National Institutes of Health.ADNFCR-8000103-ID-801491110-ADNFCR

Other news stories from 20/11/2012

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Axonn News Agency

© Copyright 2015 Zenopa Ltd